13 results on '"Jill S, Gluskin"'
Number of results to display per page
Search Results
2. Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Heather L. McArthur, Phillip Wong, Danni Yu, Courtney M. Tate, Sonya C. Chapman, Rachel Sanford, Dana E. Rathkopf, Ruslan Novosiadly, Michael J. Morris, Shanu Modi, Philomena F. McAndrew, Jonathan Landa, Praneet Kang, Suhyun Kang, David M. Hoffman, Jill S. Gluskin, Josef J. Fox, Jeremy C. Durack, Thompson N. Doman, Daniel C. Danila, Elizabeth Comen, Michelle Carlsen, Manisha Brahmachary, Victoria S. Blinder, Matthew Adamow, Susan F. Slovin, John Sae Wook Kauh, David Schaer, Christopher A. Klebanoff, and Karen A. Autio
- Abstract
Dose selection details, T cell activation/exhaustion flow assay and multiplex cytokine measurements.
- Published
- 2023
- Full Text
- View/download PDF
3. Supplementary Table S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Heather L. McArthur, Phillip Wong, Danni Yu, Courtney M. Tate, Sonya C. Chapman, Rachel Sanford, Dana E. Rathkopf, Ruslan Novosiadly, Michael J. Morris, Shanu Modi, Philomena F. McAndrew, Jonathan Landa, Praneet Kang, Suhyun Kang, David M. Hoffman, Jill S. Gluskin, Josef J. Fox, Jeremy C. Durack, Thompson N. Doman, Daniel C. Danila, Elizabeth Comen, Michelle Carlsen, Manisha Brahmachary, Victoria S. Blinder, Matthew Adamow, Susan F. Slovin, John Sae Wook Kauh, David Schaer, Christopher A. Klebanoff, and Karen A. Autio
- Abstract
Best overall response by RECIST 1.1 and PCWG2 for bone.
- Published
- 2023
- Full Text
- View/download PDF
4. Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Heather L. McArthur, Phillip Wong, Danni Yu, Courtney M. Tate, Sonya C. Chapman, Rachel Sanford, Dana E. Rathkopf, Ruslan Novosiadly, Michael J. Morris, Shanu Modi, Philomena F. McAndrew, Jonathan Landa, Praneet Kang, Suhyun Kang, David M. Hoffman, Jill S. Gluskin, Josef J. Fox, Jeremy C. Durack, Thompson N. Doman, Daniel C. Danila, Elizabeth Comen, Michelle Carlsen, Manisha Brahmachary, Victoria S. Blinder, Matthew Adamow, Susan F. Slovin, John Sae Wook Kauh, David Schaer, Christopher A. Klebanoff, and Karen A. Autio
- Abstract
Summary of noncompartmental pharmacokinetic parameters following intravenous infusion of LY3022855.
- Published
- 2023
- Full Text
- View/download PDF
5. Data from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Heather L. McArthur, Phillip Wong, Danni Yu, Courtney M. Tate, Sonya C. Chapman, Rachel Sanford, Dana E. Rathkopf, Ruslan Novosiadly, Michael J. Morris, Shanu Modi, Philomena F. McAndrew, Jonathan Landa, Praneet Kang, Suhyun Kang, David M. Hoffman, Jill S. Gluskin, Josef J. Fox, Jeremy C. Durack, Thompson N. Doman, Daniel C. Danila, Elizabeth Comen, Michelle Carlsen, Manisha Brahmachary, Victoria S. Blinder, Matthew Adamow, Susan F. Slovin, John Sae Wook Kauh, David Schaer, Christopher A. Klebanoff, and Karen A. Autio
- Abstract
Purpose:Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macrophages. This phase I study evaluated the immunologic and clinical activity, and safety profile of CSF-1R inhibition with the mAb LY3022855.Patients and Methods:Patients with advanced refractory metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (mCRPC) were treated with LY3022855 intravenously in 6-week cycles in cohorts: (A) 1.25 mg/kg every 2 weeks (Q2W); (B) 1.0 mg/kg on weeks 1, 2, 4, and 5; (C) 100 mg once weekly; (D)100 mg Q2W. mCRPC patients were enrolled in cohorts A and B; patients with MBC were enrolled in all cohorts. Efficacy was assessed by RECIST and Prostate Cancer Clinical Trials Working Group 2 criteria.Results:Thirty-four patients (22 MBC; 12 mCRPC) received ≥1 dose of LY3022855. At day 8, circulating CSF-1 levels increased and proinflammatory monocytes CD14DIMCD16BRIGHT decreased. Best RECIST response was stable disease in five patients with MBC (23%; duration, 82–302 days) and three patients with mCRPC (25%; duration, 50–124 days). Two patients with MBC (cohort A) had durable stable disease >9 months and a third patient with MBC had palpable reduction in a nontarget neck mass. Immune-related gene activation in tumor biopsies posttreatment was observed. Common any grade treatment-related adverse events were fatigue, decreased appetite, nausea, asymptomatic increased lipase, and creatine phosphokinase.Conclusions:LY3022855 was well tolerated and showed evidence of immune modulation. Clinically meaningful stable disease >9 months was observed in two patients with MBC.
- Published
- 2023
- Full Text
- View/download PDF
6. Supplementary Figure S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Heather L. McArthur, Phillip Wong, Danni Yu, Courtney M. Tate, Sonya C. Chapman, Rachel Sanford, Dana E. Rathkopf, Ruslan Novosiadly, Michael J. Morris, Shanu Modi, Philomena F. McAndrew, Jonathan Landa, Praneet Kang, Suhyun Kang, David M. Hoffman, Jill S. Gluskin, Josef J. Fox, Jeremy C. Durack, Thompson N. Doman, Daniel C. Danila, Elizabeth Comen, Michelle Carlsen, Manisha Brahmachary, Victoria S. Blinder, Matthew Adamow, Susan F. Slovin, John Sae Wook Kauh, David Schaer, Christopher A. Klebanoff, and Karen A. Autio
- Abstract
Assessment of tumor associated macrophage depletion using macrophage gene signature. The downward trend (pre vs post, indicating depletion of TAMs) of the gene signature did not appear pronounced in any of the patient samples except for patient C.
- Published
- 2023
- Full Text
- View/download PDF
7. Supplementary Table S3 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Heather L. McArthur, Phillip Wong, Danni Yu, Courtney M. Tate, Sonya C. Chapman, Rachel Sanford, Dana E. Rathkopf, Ruslan Novosiadly, Michael J. Morris, Shanu Modi, Philomena F. McAndrew, Jonathan Landa, Praneet Kang, Suhyun Kang, David M. Hoffman, Jill S. Gluskin, Josef J. Fox, Jeremy C. Durack, Thompson N. Doman, Daniel C. Danila, Elizabeth Comen, Michelle Carlsen, Manisha Brahmachary, Victoria S. Blinder, Matthew Adamow, Susan F. Slovin, John Sae Wook Kauh, David Schaer, Christopher A. Klebanoff, and Karen A. Autio
- Abstract
Summary of changes in immune cell subsets from baseline to Cycle 1 Day 8 after LY3022855 treatment.
- Published
- 2023
- Full Text
- View/download PDF
8. Supplementary Figure S1 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Heather L. McArthur, Phillip Wong, Danni Yu, Courtney M. Tate, Sonya C. Chapman, Rachel Sanford, Dana E. Rathkopf, Ruslan Novosiadly, Michael J. Morris, Shanu Modi, Philomena F. McAndrew, Jonathan Landa, Praneet Kang, Suhyun Kang, David M. Hoffman, Jill S. Gluskin, Josef J. Fox, Jeremy C. Durack, Thompson N. Doman, Daniel C. Danila, Elizabeth Comen, Michelle Carlsen, Manisha Brahmachary, Victoria S. Blinder, Matthew Adamow, Susan F. Slovin, John Sae Wook Kauh, David Schaer, Christopher A. Klebanoff, and Karen A. Autio
- Abstract
Change in tumor biomarkers by response (RECIST) during LY3022855 treatment.
- Published
- 2023
- Full Text
- View/download PDF
9. Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Heather L. McArthur, Phillip Wong, Danni Yu, Courtney M. Tate, Sonya C. Chapman, Rachel Sanford, Dana E. Rathkopf, Ruslan Novosiadly, Michael J. Morris, Shanu Modi, Philomena F. McAndrew, Jonathan Landa, Praneet Kang, Suhyun Kang, David M. Hoffman, Jill S. Gluskin, Josef J. Fox, Jeremy C. Durack, Thompson N. Doman, Daniel C. Danila, Elizabeth Comen, Michelle Carlsen, Manisha Brahmachary, Victoria S. Blinder, Matthew Adamow, Susan F. Slovin, John Sae Wook Kauh, David Schaer, Christopher A. Klebanoff, and Karen A. Autio
- Abstract
Time plots of circulating levels of interleukin-34
- Published
- 2023
- Full Text
- View/download PDF
10. Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- Author
-
Daniel C. Danila, Thompson N. Doman, Jonathan Landa, David Schaer, Shanu Modi, Elizabeth A. Comen, Matthew Adamow, Jill S. Gluskin, Susan F. Slovin, Michael J. Morris, Suhyun Kang, Manisha Brahmachary, Sonya C. Chapman, David M. J. Hoffman, Rachel Sanford, Jeremy C. Durack, Josef J. Fox, Michelle Carlsen, Ruslan D. Novosiadly, Philomena McAndrew, John S. Kauh, Dana E. Rathkopf, Courtney M. Tate, Danni Yu, Karen A. Autio, Victoria S. Blinder, Phillip Wong, Praneet Kang, Christopher A. Klebanoff, and Heather L. McArthur
- Subjects
Adult ,Male ,0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Drug-Related Side Effects and Adverse Reactions ,Nausea ,medicine.medical_treatment ,Lipopolysaccharide Receptors ,Breast Neoplasms ,Receptor, Macrophage Colony-Stimulating Factor ,Asymptomatic ,Gastroenterology ,Article ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Immunologic Factors ,Neoplasm Metastasis ,Adverse effect ,Aged ,Cell Proliferation ,Neoplasm Staging ,Aged, 80 and over ,biology ,business.industry ,Receptors, IgG ,Antibodies, Monoclonal ,Immunosuppression ,Middle Aged ,medicine.disease ,Metastatic breast cancer ,Clinical trial ,Prostatic Neoplasms, Castration-Resistant ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Female ,Creatine kinase ,medicine.symptom ,business - Abstract
Purpose: Tumor-associated macrophages correlate with increased invasiveness, growth, and immunosuppression. Activation of the colony-stimulating factor-1 receptor (CSF-1R) results in proliferation, differentiation, and migration of monocytes/macrophages. This phase I study evaluated the immunologic and clinical activity, and safety profile of CSF-1R inhibition with the mAb LY3022855. Patients and Methods: Patients with advanced refractory metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (mCRPC) were treated with LY3022855 intravenously in 6-week cycles in cohorts: (A) 1.25 mg/kg every 2 weeks (Q2W); (B) 1.0 mg/kg on weeks 1, 2, 4, and 5; (C) 100 mg once weekly; (D)100 mg Q2W. mCRPC patients were enrolled in cohorts A and B; patients with MBC were enrolled in all cohorts. Efficacy was assessed by RECIST and Prostate Cancer Clinical Trials Working Group 2 criteria. Results: Thirty-four patients (22 MBC; 12 mCRPC) received ≥1 dose of LY3022855. At day 8, circulating CSF-1 levels increased and proinflammatory monocytes CD14DIMCD16BRIGHT decreased. Best RECIST response was stable disease in five patients with MBC (23%; duration, 82–302 days) and three patients with mCRPC (25%; duration, 50–124 days). Two patients with MBC (cohort A) had durable stable disease >9 months and a third patient with MBC had palpable reduction in a nontarget neck mass. Immune-related gene activation in tumor biopsies posttreatment was observed. Common any grade treatment-related adverse events were fatigue, decreased appetite, nausea, asymptomatic increased lipase, and creatine phosphokinase. Conclusions: LY3022855 was well tolerated and showed evidence of immune modulation. Clinically meaningful stable disease >9 months was observed in two patients with MBC.
- Published
- 2020
- Full Text
- View/download PDF
11. Differentiation of mucinous cysts and simple cysts of the liver using preoperative imaging
- Author
-
Caitlin A, McIntyre, Jeffrey, Girshman, Debra A, Goldman, Mithat, Gonen, Kevin C, Soares, Alice C, Wei, Vinod P, Balachandran, T Peter, Kingham, Jeffrey A, Drebin, William R, Jarnagin, Jill S, Gluskin, Michael I, D'Angelica, and Scott R, Gerst
- Subjects
Pancreatic Neoplasms ,Liver ,Mucocele ,Humans ,Tomography, X-Ray Computed ,Magnetic Resonance Imaging ,Retrospective Studies - Abstract
Preoperative radiographic differentiation of mucinous cystic neoplasms (MCN) and simple cysts (SLC) of the liver is challenging. Previous data have demonstrated that the finding of septations arising from the cyst wall without indentation on cross-sectional imaging is associated with MCN. We aim to assess whether this radiographic feature is diagnostic of MCN.A prospectively maintained database was queried for patients with a preoperative diagnosis of a cystic liver lesion who subsequently underwent operative intervention. The feature of septations without indentation of the cyst wall was evaluated on cross-sectional imaging obtained within 3 months of operation. Imaging was independently evaluated by three radiologists blinded to pathology and interobserver agreement was compared to assess the diagnostic accuracy of this feature as well as the overall likelihood of the lesion representing a MCN.There were 95 patients who met inclusion criteria; 80 (84%) had SLC on pathology, while 15 (16%) had MCN. Presence of septa without indentation of cyst wall had high sensitivity (range 80-87%), but low specificity (range 48-66%). Interobserver percent agreement (PA) was 51% [κ = 0.35 (95% CI 0.22-0.47)]. Sensitivity among the three radiologists ranged between 20 and 80% and specificity between 71 and 91% for the likelihood of the lesion representing MCN versus SLC, with an area under the curve (AUC) of 0.67-0.79; however, interobserver agreement was fair [κ = 0.40 (95% CI 0.25-0.55), PA = 67%].The presence of septations without indentation of cyst wall demonstrates adequate sensitivity to differentiate MCN and SLC. However, there is variability for detection of this feature and therefore, it alone is of limited clinical value.
- Published
- 2021
12. Contributors
- Author
-
Ghassan K. Abou-Alfa, Jad Abou Khalil, Pietro Addeo, N. Volkan Adsay, Anil Kumar Agarwal, Farzad Alemi, Peter J. Allen, Ahmed Al-Mukhtar, Thomas A. Aloia, Jesper B. Andersen, Christopher D. Anderson, Vittoria Arslan-Carlon, Horacio J. Asbun, Béatrice Aussilhou, Joseph Awad, Daniel Azoulay, Philippe Bachellier, Talia B. Baker, Zubin M. Bamboat, Jeffrey Stewart Barkun, Claudio Bassi, Olca Basturk, Rachel E. Beard, Pierre Bedossa, Jacques Belghiti, Omar Bellorin-Marin, Marc G.H. Besselink, Anton J. Bilchik, Leslie H. Blumgart, Franz Edward Boas, Lynn A. Brody, Karen T. Brown, Jordi Bruix, David A. Bruno, Elizabeth M. Brunt, Justin M. Burns, Giovanni Butturini, Juan Carlos Caicedo, Mark P. Callery, Abdul Saied Calvino, Danielle H. Carpenter, C. Ross Carter, François Cauchy, Chung Yip Chan, See Ching Chan, William C. Chapman, Daniel Cherqui, Clifford S. Cho, Jin Wook Chung, Jesse Clanton, Bryan Marshall Clary, Sean Patrick Cleary, Kelly M. Collins, John Barry Conneely, Louise C. Connell, Carlos U. Corvera, Guido Costa, Anne M. Covey, Jeffrey S. Crippin, Kristopher P. Croome, Hany Dabbous, Michael I. D'Angelica, Michael D. Darcy, Jeremy L. Davis, Jeroen de Jonge, Ronald P. DeMatteo, Danielle K. DePeralta, Niraj M. Desai, Eduardo de Santibañes, Martin de Santibañes, Euan J. Dickson, Christopher John DiMaio, Richard Kinh Gian Do, Safi Dokmak, Marcello Donati, M.B. Majella Doyle, Vikas Dudeja, Mark Dunphy, Truman M. Earl, Tomoki Ebata, Imane El Dika, Yousef El-Gohary, Itaru Endo, C. Kristian Enestvedt, N. Joseph Espat, Cecilia G. Ethun, Sheung Tat Fan, Paul T. Fanta, Olivier Farges, Cristina R. Ferrone, Ryan C. Fields, Mary Fischer, Sarah B. Fisher, Devin C. Flaherty, Yuman Fong, Scott L. Friedman, Ahmed Gabr, John R. Galloway, David A. Geller, Hans Gerdes, Scott R. Gerst, George K. Gittes, Jaime Glorioso, Jill S. Gluskin, Brian K.P. Goh, Stevan A. Gonzalez, Karyn A. Goodman, Gregory J. Gores, Eduardo H. Gotuzzo, Dirk J. Gouma, Paul D. Greig, James F. Griffin, Christopher M. Halloran, Neil A. Halpern, Chet W. Hammill, Paul D. Hansen, James J. Harding, Ewen M. Harrison, Werner Hartwig, Kiyoshi Hasegawa, Jaclyn F. Hechtman, Julie K. Heimbach, William S. Helton, Alan W. Hemming, J. Michael Henderson, Asher Hirshberg, James R. Howe, Christopher B. Hughes, Christine Iacobuzio-Donahue, William R. Jarnagin, Roger L. Jenkins, Zeljka Jutric, Christoph Kahlert, Joseph Ralph Kallini, Ivan Kangrga, Paul J. Karanicolas, Seth S. Katz, Steven C. Katz, Kaitlyn J. Kelly, Nancy E. Kemeny, Eugene P. Kennedy, Korosh Khalili, Adeel S. Khan, Saboor Khan, Heung Bae Kim, T. Peter Kingham, Allan D. Kirk, David S. Klimstra, Michael Kluger, Stuart J. Knechtle, Jonathan B. Koea, Norihiro Kokudo, Dionysios Koliogiannis, David A. Kooby, Kevin Korenblat, Simone Krebs, Michael J. LaQuaglia, Michael P. LaQuaglia, Nicholas F. LaRusso, Alexis Laurent, Konstantinos N. Lazaridis, Julie N. Leal, Eliza J. Lee, Major Kenneth Lee, Ser Yee Lee, Riccardo Lencioni, Alexandre Liccioni, Michael E. Lidsky, Chung-Wei Lin, David C. Linehan, Roberto Carlos Lopez-Solis, Jeffrey A. Lowell, David C. Madoff, Jason Maggi, Shishir K. Maithel, Ali W. Majeed, Peter Malfertheiner, Giuseppe Malleo, Shennen A. Mao, Giovanni Marchegiani, Luis A. Marcos, James F. Markmann, J. Wallis Marsh, Robert C.G. Martin, Ryusei Matsuyama, Matthias S. Matter, Francisco Juan Mattera, Jessica E. Maxwell, Oscar M. Mazza, Ian D. McGilvray, Colin J. McKay, Doireann M. McWeeney, Jose Melendez, Robin B. Mendelsohn, George Miller, Klaus E. Mönkemüller, Ryutaro Mori, Vitor Moutinho, Masato Nagino, David M. Nagorney, Satish Nagula, Attila Nakeeb, Geir I. Nedredal, John P. Neoptolemos, James Neuberger, Scott L. Nyberg, Rachel O'Connor, John G. O'Grady, Frances E. Oldfield, Karl J. Oldhafer, Kim M. Olthoff, Susan L. Orloff, Alessandro Paniccia, Valérie Paradis, Rowan W. Parks, Gérard Pascal, Stephen M. Pastores, Timothy M. Pawlik, Venu G. Pillarisetty, James Francis Pingpank, C. Wright Pinson, Henry Anthony Pitt, James J. Pomposelli, Fabio Procopio, Michael J. Pucci, Motaz Qadan, Kheman Rajkomar, Srinevas K. Reddy, Maria E. Reig, Joseph Arturo Reza, John Paul Roberts, Piera Marie Cote Robson, Flavio G. Rocha, Garrett Richard Roll, Sean M. Ronnekleiv-Kelly, Alexander S. Rosemurgy, Charles B. Rosen, Pierre F. Saldinger, Riad Salem, Suhail Bakr Salem, Roberto Salvia, Charbel Sandroussi, Dominic E. Sanford, Olivier Scatton, Mark Andrew Schattner, William Palmer Schecter, Hans Francis Schoellhammer, Richard D. Schulick, Lawrence H. Schwartz, Kevin N. Shah, Ross W. Shepherd, Hiroshi Shimada, Masafumi Shimoda, Junichi Shindoh, Hosein Shokouh-Amiri, Jason K. Sicklick, Robert H. Siegelbaum, Gagandeep Singh, Rory L. Smoot, Stephen B. Solomon, Olivier Soubrane, Nicholas Spinelli, John A. Stauffer, Lygia Stewart, Matthew S. Strand, James H. Tabibian, Guido Torzilli, James F. Trotter, Simon Turcotte, Yumirle P. Turmelle, Demetrios J. Tzimas, Thomas Van Gulik, Andrea Vannucci, Jean-Nicolas Vauthey, Diana Vetter, Valérie Vilgrain, Alejandra Maria Villamil, Louis P. Voigt, Charles M. Vollmer, Jack R. Wands, Julia Wattacheril, Sharon Marie Weber, Matthew J. Weiss, Jürgen Weitz, Jens Werner, Megan Winner, John Wong, Dennis Yang, Hooman Yarmohammadi, Charles J. Yeo, Theresa Pluth Yeo, Chang Jin Yoon, Adam Yopp, D. Owen Young, Kai Zhao, Gazi B. Zibari, and George Zogopoulos
- Published
- 2017
- Full Text
- View/download PDF
13. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies
- Author
-
Andrea, Cercek, Taryn M, Boucher, Jill S, Gluskin, Ariel, Aguiló, Joanne F, Chou, Louise C, Connell, Marinela, Capanu, Diane, Reidy-Lagunes, Michael, D'Angelica, and Nancy E, Kemeny
- Subjects
Adult ,Aged, 80 and over ,Male ,Adolescent ,Liver Neoplasms ,Antineoplastic Agents ,Middle Aged ,Survival Analysis ,Dexamethasone ,Article ,Young Adult ,Treatment Outcome ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Infusions, Intra-Arterial ,Female ,Colorectal Neoplasms ,Floxuridine ,Aged ,Follow-Up Studies ,Retrospective Studies - Abstract
To evaluate the role of hepatic arterial infusion (HAI) in patients with metastatic colorectal cancer (mCRC) liver metastases (LM) refractory to oxaliplatin, irinotecan, and fluorouracil-based treatments.A search identified patients with mCRC treated after tumor progression on at least three standard systemic therapies.One hundred and ten patients met criteria for inclusion (i.e., progression on at least three standard agents). Fifty seven patients had LM-only and 53 patients had LM and low volume extrahepatic metastases (LME). Patients with LM-only and LME had a response rate (RR) of 33% and 36%, median survival of 20 months and 11.4 months, respectively. Patients with LM-only had progression free survival of 6 months and hepatic progression free survival of 7.56 months. In a secondary analysis, 46 patients were RECIST-refractory to all standard therapies: LM-only (n = 24) and LME (n = 22). LM-only and LME had a RR of 29% and 36%, and median survival 17.2 months and 9.1 months, respectively.Patients with refractory mCRC LM can achieve a response to HAI resulting in antitumor activity and improvement in survival. Responses are rarely seen in such heavily treated patients with systemic therapy alone, suggesting a regional directed approach is useful. J. Surg. Oncol. 2016;114:655-663. © 2016 Wiley Periodicals, Inc.
- Published
- 2016
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.